Mayo Clinic Q&A

From complex or serious conditions like cancer and heart disease to the latest news on research and wellness, host Dr. Halena Gazelka asks the questions and gets easy-to-understand answers from Mayo Clinic experts

Episodes Mayo Clinic experts discuss new Alzheimer's treatment option

an elderly white man with grey hair looking sad, worried, forgetful holding his head with his hands

Mayo Clinic experts discuss new Alzheimer’s treatment option
June 15, 2021

Last week, the Food and Drug Administration approved aducanumab to treat Alzheimer’s disease, which is a progressive brain disorder that is the most common cause of dementia. 

Aducanumab targets amyloid plaques in the brain that are believed to be an essential component of Alzheimer’s disease. But what does the approval of a new Alzheimer's drug mean for patients?

On the Mayo Clinic Q&A podcast, Dr. Ronald Petersen, a Mayo Clinic neurologist and director of Mayo Clinic’s Alzheimer’s Disease Research Center, and Dr. David Knopman, a Mayo Clinic neurologist, discuss the challenges ahead to identify the appropriate patients for treatment with aducanumab.